The mesoporous silica nanoparticles target drug delivery system was validated by Micro PLUS Nano Flow Cytometer

也可用於 / Also available in: 简体中文 (Chinese (Simplified))

ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

Targeted delivery of chemotherapeutic drugs to cancer cells is a holy grail to pancreatic cancer treatment. Many pancreatic cancer patients who undergone treatment with systemic chemotherapy would withdraw from treatment during the treatment course particularly after experiencing a high level of discomfort from collateral toxicity caused to non-cancerous cells by the chemotoxic drugs. Targeted delivery of chemotoxic drugs can reduce such collateral toxicity so a higher concentration of chemotoxic drugs can be used and the efficacy of the drugs may be improved. In this article, the authors have developed a pancreatic cancer-specific protease-dependent drug delivery system consisting of mesoporous silica nanoparticles (MSN) enclosed in a capsule. The capsule is constituted with an avidin-biotin gatekeeper system as the cap and the cap will be removed by proteolytic cleavage by PDAC-expressed proteases. The in vitro efficacy of the delivery system has been validated with Apogee A60 Micro-PLUS and the result is thus far promising. Apogee A60 Micro-PLUS plays a significant role to determine the successful assembly of the delivery system and cleavage of the ADAM9 peptide linker (De-capping). Equipping with 4 separated lasers and 12 optical detectors, Apogee A60 Micro-PLUS can precisely detect 163 to 189 nm MSN (Lower detection limit is 100nm silica beads) and support multi-parametric analysis mode to correctly identify the target population of interest.

Slapak, E.J.; Kong, L.; el Mandili, M.; Nieuwland, R.; Kros, A.; Bijlsma, M.F.; Spek, C.A. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Cancers 2021, 13, 3321.



About the Author

Alfred Leung